On January 7, Hotgen Biotech released a performance forecast. The company expects the net profit attributable to the shareholders of the listed company from January to December 2021 to be CNY 2 billion to CNY 2.35 billion, with a year-on-year change of 1684.65% to 1996.97%.

The main reason for performance changes in the current period:

In the first half of 2021, the company's New Coronavirus antigen detection kit was earlier approved by the BfArM for home free testing, which could be sold in Germany's supermarket, drugstores, Internet stores, and so on, resulting in the explosive growth of foreign trade orders in the first half of the year. In the second half of the year, New Coronavirus antigen detection kit developed by the company has obtained self-testing registration / filing of CE and major economies such as the British MHRA and ANSM, and was affected by the COVID-19 Delta and the Omicron in the fourth quarter, and COVID-19 in Europe and Southeast Asia remained at a high level. When the demand for COVID-19 antigen detection reagents increased significantly, the revenue of overseas covid-19 detection reagents increased significantly; As a result, the company's performance in 2021 achieved large-scale growth compared with the same period last year.

Beijing Hotgen Biotech Co., Ltd. (abbreviated as Hotgen Biotech, stock code: 688068) was established in June 2005, which is a high-tech enterprise focusing on the research& development, manufacture and sales of medical and public safety inspection products of in vitro diagnostics (IVD) in the field of biomedicine, as well as landed on the China Sci-Tech innovation board (STAR Market) in September 2019.

After serval years of Research& development, Hotgen Biotech has developed an in vitro diagnostic reagent bioactive raw material development platform, a sugar chain abnormal protein detection (sugar capture) R&D technology platform, a Magnetic particles chemiluminescence R&D technology platform, a Up-converting Phosphor R&D technology platform, and a colloidal gold immune layer, The eight major technology platforms, such as the precipitation R&D platform, enzyme-linked immunoassay R&D technology platform, molecular diagnostics R&D platform, and instrument R&D technology platform, form a closed-loop system for in vitro diagnostic R&D and production. Hotgen Biotech has established a complete full level immunodiagnostic technology platform, from high-precision Up-converting Phosphor POCT (UPT series) to small, medium and large single- cartridge chemiluminescence platforms (MQ60 series), and then to large-scale full-automatic chemiluminescence Platform (C2000), which realizes the application of the immune diagnostic platform in the field of full diagnostic scenarios. Supporting products are widely used in the clinical and public safety fields. Specific users include hospitals at all levels, township health centers, third-party testing centers, and medical institutions, as well as medical and health institutions, as well as disease control centers, public security, fire protection, military, ports, food and medicine. Supervision, food and feed enterprises and other public safety fields.

Hotgen Biotech has won the second prize of the National Technology Invention Award, the Gold Medal of Independent Innovation, and the second prize of the Chinese Medical Science and Technology Award; In 2018, Hotgen Biotech was awarded the second prize of the "Technical Invention Category of China Rare Earth Science and Technology Award" by the China Rare Earth Society; Top 100 Private Scientific and Technological Innovations "and" Top 100 Medical Enterprises of the Future "; and" Postdoctoral Scientific Research Workstation "; major science and technology projects in the 12th and 13th five years, 863 plan, science and technology projects of the Beijing Science and Technology Commission, and Zhongguancun High Precision The project's major cutting-edge original technological achievements transformation and industrialization project.

Since its establishment, the company has continuously grown its business and has now achieved group development. At present, Hotgen (Langfang), Hotgen (Jilin), Weikekang Technology, Shunjing Biological and many other subsidiaries have been established. Hotgen Biotech marketing and service network has covered all regions of the country. Each province is equipped with professional technical service engineers, academic engineers, etc. who are responsible for pre-sales and after-sales work to meet customer needs. The company takes "developing biotechnology and benefiting human health" as its mission, "quality determines the company's life and death, customers determine the company's success or failure, talents determine the company's rise and fall, innovation determines the company's future" as its core values, and "tests because of me advanced" as its philosophy , High ambitions, technological entrepreneurship, and industrial prosperity!

CACLP2022 Booth No. of Hotgene: A4-2809